Pancreatic Cancer Clinical Trials in San Francisco

Showing 61-80 of 98 trials

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

NCT01453153

Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated pancreatic cancer patients. Phase 2: Randomized, double blind study to compare the effect of overall survival of gemcitabine plus PEGPH20 vs gemcitabine plus placebo in Stage IV previously untreated pancreatic cancer patients.

Stage IV Pancreatic Cancer

Halozyme Therapeutics28 participantsStarted Sep 2011

Fayetteville, Arkansas, United States • San Francisco, California, United States • Indianapolis, Indiana, United States +9 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

NCT02004262

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma

2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer

Aduro Biotech, Inc.303 participantsStarted Feb 2014

Scottsdale, Arizona, United States • La Jolla, California, United States • San Francisco, California, United States +18 more locations

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Pancreatic Cancer Trials in Other Cities

Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

Permission to Collect Blood Over Time for Research

Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

Other Conditions in San Francisco